Rucaparib
Small molecule
Evidence outlook
Approved: Ovarian Cancer, Metastatic Castration-Resistant Prostate Cancer, Prostate Cancer
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Also approved (1)
- Rubraca is indicated as monotherapy for the maintenance treatment of adult patients with advanced (FIGO Stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy. Rubraca is indicated as monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
ARIEL3 NCT01968213 · Ovarian Cancer This was a randomized, double-blind, placebo-controlled phase 3 trial involving 564 participants. The prespecified primary endpoint was the clinical outcome of progression-free survival or death, and it was significantly improved with rucaparib compared with placebo (hazard ratio 0.365; p<0.0001). Registry: NCT01968213 | 3 | Disease Progression According to RECIST Version 1.1, as Assessed by the Investigator, or Death From Any Cause (Investigator Progression Free Survival as Per invPFS) (Every 12 calendar weeks (within 7 days prior is permitted) after start of treatment until treatment discontinuation due to disease progression. Total follow-up was up to approximately 3 years.) 2017-04-01 | Disease Progression According to RECIST Version 1.1, as Assessed by the Investigator, or Death From Any Cause (Investigator Progression Free Survival as Per invPFS) (Every 12 calendar weeks (within 7 days prior is permitted) after start of treatment until treatment discontinuation due to disease progression. Total follow-up was up to approximately 3 years.): Rucaparib 600 mg Tablets 10.8 Months (95% CI 8.3 to 11.4) | Placebo Tablets 5.4 Months (95% CI 5.3 to 5.5) | Reliable signal | link ↗ |
View 2 more trials
ATHENA NCT03522246 · Ovarian Cancer Registry: NCT03522246 | 3 | Monotherapy Arm B and Arm D: Investigator Assessed Progression-free Survival (PFS) (From randomization until disease progression (up to the primary data analysis at approximately 39 months)); Monotherapy Arm B and Arm D: Investigator Assessed PFS (From randomization until disease progression (up to the primary data analysis at approximately 39 months)); Combination Therapy Arm A and Arm B: Investigator Assessed PFS (From randomization until disease progression (up to the combination therapy interim analysis at approximately 66 months)) 2024-05-20 | Results posted on ClinicalTrials.gov. Key figures are not recorded here. | not yet graded | link ↗ |
NCT02855944 NCT02855944 · Ovarian Cancer Registry: NCT02855944 | 3 | Investigator Assessed Progression-Free Survival (invPFS) by RECIST Version 1.1 for Rucaparib Versus Chemotherapy (Efficacy Population) (Assessments every 8 weeks from Cycle 1 Day 1 (C1D1) until disease progression, death, or initiation of subsequent treatment. After 18 months on study, assessments every 16 weeks. Total follow-up was up to approximately 3.5 years.); Investigator Assessed Progression-Free Survival (invPFS) by RECIST Version 1.1 for Rucaparib Versus Chemotherapy (ITT Population) (Assessments every 8 weeks from C1D1 until disease progression, death, or initiation of subsequent treatment. After 18 months on study, assessments every 16 weeks. Total follow-up was up to approximately 3.5 years.) 2020-12-03 | Investigator-assessed PFS, rucaparib vs chemotherapy: efficacy population median 7.4 vs 5.7 months, HR 0.639 (95% CI 0.489 to 0.835), p=0.0010; ITT 7.4 vs 5.7 months, HR 0.665 (95% CI 0.516 to 0.858), p=0.0017 (CT.gov posted results). | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (8)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (29)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (11)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (12)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Competitive landscape
This drug's own stage for Metastatic Castration-Resistant Prostate Cancer: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Rucaparib: this drug | Approved | Small molecule | PARP (poly ADP-ribose polymerase) enzymes, PARP1/2 | Partial signal | No reviewed efficacy summary in this indication | |
| Docetaxel (Taxotere) | Approved | Small molecule | Microtubules (tubulin) | not yet graded | No reviewed efficacy summary in this indication | |
| Olaparib | Approved | Small molecule | PARP | not yet graded | No reviewed efficacy summary in this indication | |
| Talazoparib | Approved | Small molecule | PARP | not yet graded | No reviewed efficacy summary in this indication | |
| Elfetabart Drozuntecan | Phase 3 | Antibody–drug conjugate | B7-H3 | not yet graded | No reviewed efficacy summary in this indication | |
| Fluzoparib | Phase 3 | Small molecule | PARP (poly ADP-ribose polymerase), specifically PARP-1 | not yet graded | No reviewed efficacy summary in this indication | |
| HRS-4357 | Phase 3 | Undisclosed | PSMA | not yet graded | No reviewed efficacy summary in this indication | |
| Ifinatamab Deruxtecan | Phase 3 | Antibody–drug conjugate | B7-H3 | not yet graded | No reviewed efficacy summary in this indication | |
| Mevrometostat | Phase 3 | Small molecule | EZH2 | not yet graded | No reviewed efficacy summary in this indication | |
| Opevesostat | Phase 3 | Small molecule | — | not yet graded | No reviewed efficacy summary in this indication | |
| Pasritamig | Phase 3 | Multispecific antibody | — | not yet graded | No reviewed efficacy summary in this indication | |
| Zadavotide Guraxetan | Phase 3 | Radioconjugate (actinium-225) | PSMA | not yet graded | No reviewed efficacy summary in this indication | |
| Luxdegalutamide | Phase 2 | Small molecule | Androgen receptor, Androgen receptor (degrader) | not yet graded | No reviewed efficacy summary in this indication | |
| ABBV-969 | Phase 1 | Undisclosed | PSMA / STEAP1 | not yet graded | No reviewed efficacy summary in this indication | |
| AKY-2519 | Phase 1 | Radiopharmaceutical | B7-H3-targeted radioligand therapy | not yet graded | No reviewed efficacy summary in this indication | |
| BPX-601 | Phase 1 | Cell therapy | PSCA | not yet graded | No reviewed efficacy summary in this indication | |
| RG6852 | —(overall) | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(5 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Rucaparib to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.